• October 6, 2026
Alcon Launches New Systane PRO Preservative-Free Eye Drops in Canada

Alcon announced the launch of Systane® PRO Preservative-Free (PF) in Canada as Systane’s most advanced formula.…

  • August 17, 2026
World Council of Optometry, Alcon, and IACLE Partner to Advance Dry Eye Education

The World Council of Optometry (WCO) and Alcon dry eye initiative is partnering with the International…

  • February 18, 2026
Alcon Expands Portfolio with U.S. Launch of TOTAL30, the World’s Only Water Gradient Multifocal Toric Lens

Provides excellent end of day comfort even on day 30,^ helping patients stay in contact lenses†comfortably1…

  • February 3, 2026
Alcon Debuts Groundbreaking PRECISION7 in Canada, a One-Week Replacement Contact Lens

Alcon announced the Canadian launch of PRECISION7® sphere and toric, the only one-week replacement contact lens…

  • January 29, 2026
World Council of Optometry and Alcon Expand Partnership to Promote Dry Eye Disease Education

The World Council of Optometry (WCO) and Alcon have renewed their education initiative to advance dry eye…

  • December 9, 2025
Alcon Announces Amended Merger Agreement with STAAR Surgical

Alcon announced that it has entered into an amended merger agreement for the acquisition of…

  • August 11, 2025
Alcon Agrees to Acquire STAAR Surgical

Alcon and STAAR Surgical Company the manufacturer of the Implantable Collamer Lens (ICL), announced the companies…

  • July 8, 2025
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)

Alcon announced its intention to acquire LumiThera and its PBM device for the treatment of…

  • July 1, 2025
Alcon Canada Earns Global Recognition as a Top Employer

Alcon announced that Alcon Canada has been certified as a Top Employer in Canada by…

  • April 1, 2025
Alcon Acquires Majority Interest in Aurion Biotech, to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced…